BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37357252)

  • 1. YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
    Chen G; Ren D; Wang Y; Wang H; Zhang J; Yang S
    J Mol Histol; 2023 Aug; 54(4):365-377. PubMed ID: 37357252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
    Wang H; Cai H; Li L
    Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
    Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
    Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma.
    Zhang X; Cai X
    Medicine (Baltimore); 2022 Nov; 101(45):e31195. PubMed ID: 36397411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic Analyses of the Role of the Reader Protein of
    Shao XY; Dong J; Zhang H; Wu YS; Zheng L
    Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
    Song Y; Sun Y; Sun T; Tang R
    Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
    Mu Z; Dong D; Sun M; Li L; Wei N; Hu B
    Front Oncol; 2020; 10():1566. PubMed ID: 33102202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.
    Cao J; Yu C
    Comb Chem High Throughput Screen; 2023; 26(3):507-516. PubMed ID: 35400336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.
    Chen X; Mo S; Zong L; Yu S; Lu Z; Chen J
    Neuroendocrinology; 2022; 112(12):1187-1199. PubMed ID: 35609514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
    Yu ZL; Zhu ZM
    Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
    Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
    Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
    Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
    Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
    Su G; Liu T; Han X; Sun H; Che W; Hu K; Xiao J; Li Y; Liu Y; Li W; Mei H
    Front Pharmacol; 2021; 12():709548. PubMed ID: 34512342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
    Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
    Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.